MAPT and Alzheimer disease: The development of AD is currently understood as a cascade of pathophysiological events, where initial Aβ aggregation is assumed to trigger the subsequent trans-neuronal spread of tau pathology, ensuing neurodegeneration and cognitive decline [2–5].